Scheduled to kick off on Tuesday, September 15th, 2020 at 9:00 AM EST, the 3rd Annual International Cannabinoid-Derived Pharmaceuticals Summit is expected to feature 40 different speakers ranging from research and development leaders to regulatory experts and more.
In alphabetical order of the company, firm, regulatory body, or university that they represent, here are the 30+ speakers expected to present at this year’s ICDP Summit.
- Mark Rosenfeld: Chief Executive Officer and Chief Science Officer, Ananda Scientific
- Andy Yates: Chief Scientific Officer, Artelo Biosciences
- Greg Gorgas: President and Chief Executive Officer, Artelo Biosciences
- Boaz Hirshberg: Executive Vice President, Chief Medical Officer, Head of Global Development, BOL Pharma
- Matthew Callahan: Executive Chairman, Botanix Pharmaceuticals Ltd. (ASX:BOT)
- Hunter Land: Associate Director of Cannabinoid Research, Canopy Growth Corporation (TSX:WEED) (NYSE:CGC) (FRA:11L1)
- Hongfeng Deng: Director and Head of Medicinal Chemistry, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
- Seth Adler: Host, Cannabis Economy Podcast
- Monica Taing: Board Member, Doctors for Cannabis Regulation
- Brian Murphy: Chief Executive Officer, Emerald Bioscience Inc. (OTC:EMBI)
- Caio Santos Abreu: Founder and Chief Executive Officer, Entourage Phytolab
- Manuel Alfaro De Pra: Research and Development Coordinator, Entourage Phytolab
- Bruce Mackler: Executive Vice President, Regulatory Affairs, Ethicann Pharmaceuticals
- Brandon Price: Executive Vice President, Business Development, Ethicann Pharmaceuticals
- Andrea Lee Small-Howard: Chief Science Officer, Director and Board Member GBS Global Biopharma, Inc./ GB Sciences, Inc. (OTC:GBLX)
- Pavel Pachta: Director for International Regulatory Affairs, International Cannabis and Cannabinoids Institute (ICCI)
- Rob Dhoble: Managing Director, Havas ECS
- Dean Petkanas: Chief Executive Officer, Kannalife
- Rod Kight: Attorney, Kight Law Office
- Alex Makriyannis: Director, Center for Drug Discovery, Northeastern University
- Saeid Babaei: Chief Executive Officer, Orpheus Medica
- Patrick Gray: Chief Executive Officer, Pascal Biosciencs Inc.
- Gary Hiller: Chief Operating Officer, Phytecs
- Scott McAuley: Healthcare and Biotechnology Analyst, Paradigm Capital
- Josh Hoerner: General Manager, Purisys
- Michael Freeman: Equity Research Associate, Raymond James
- Rahul Sarugaser: Managing Director, Raymond James
- Andrea Leone-Bay: Founder and Chief Scientific Officer, Receptor Life Sciences
- Jeff Margolis: Chief Financial Officer, RespireRX Pharmaceuticals Inc. (OTC:RSPI)
- Aurelia De Pauw: Vice President, Clinical Programs and Medical Affairs, Tetra Bio-Pharma Inc. (TSXV:TBP) (OTC:TBPMF) (FRA:JAM1)
- Dominic Chiapperino: Director – Controlled Substances Division, US Food and Drug Administration (FDA)
- Steven James: Adjunct Associate Professor of Psychiatry, University of California, San Diego
- Igor Kovalchuk: Professor, University of Lethbridge
- Jerry Bryant: Managing Member and Chief Scientific Officer, Vyripharm Biopharmaceuticals
- Allyn Howlett: Professor, Wake Forest School of Medicine
- Mara Gordon: Founder, Zelda Therapeutics Ltd. (ASX:ZLD) (OTC:ZLDAF) (FRA:G1G)
- Oludare Odumosu: Managing Director, Zelira Therapeutics Inc.
- Richard Hopkins: Managing Director ex USA, Zelira Therapeutics Inc.
In the last twelve months, we’ve seen a measurable increase in the clinical pipeline of cannabis-derived pharmaceuticals as the worldwide sales of GW Pharmaceuticals’ Epidiolex was on the rise. This leads us to believe that any one of these companies could one day become the next GW Pharma.
Be sure to subscribe to cannabinoid biotech updates here so you never miss an important update.
Get Real-Time Updates from MJobserver.com
